We used cefamandole in the initial treatment of 34 children (10 months to 15 years of age) with suspected bone, joint, or soft tissue infections. The miniimal inhibitory concentration of organisms encountered ranged between 0.015 and 2 ,ug/ml. At 1 h after intravenous infusion of 25 mg/kg, the mean serum level of cefamandole was 26.2 ,ug/ml (range, 8.9 to 47.5 jig/ml), and at 3 h the level was 1.8
diffuse well into synovial fluid, with joint fluid levels between 5 and 40,ug/ml. The drug was tolerated well. Cefamandole appears to be a reasonable alternative in the initial treatment of skeletal infections in children, but needs to be administered every 4 h to maintain suprainhibitory serum levels between doses.
Cefamandole is a relatively new semisynthetic cephalosporin antibiotic with a broader spectrum of antimicrobial activity than previously available cephalosporins (7, 12) . The majority of skeletal infections in children are caused by Staphylococcus aureus. In children under 2 years of age, Haemophilus influenzae is the most common cause of pyogenic arthritis. Since cefamandole is active against S. aureus and other gram-positive cocci, as well as against H. influenzae (including ampicillin-resistant strains) (5, 12) , we evaluated the usefulness of cefamandole in the initial treatment of bone and joint infections in children. We also studied the pharmacokinetics of the drug and its diffusion into joint fluid.
MATERIALS AND METHODS Patient selection. Children over 6 months of age with suspected skeletal infections were enrolled in the study after informed parental consent was obtained. The diagnosis was established by isolation of an organism from cultures of blood or material aspirated from the site of infection or both. Of the 34 children who were entered in the study initially, 6 Drug administration. Cefamandole was adxministered at a daily dose of 150 mg/kg. The drug was initially given as a 30-min intravenous infusion every 6 h as suggested by the manufacturer. Because information obtained from the first few patients showed that at 4 h after the end of infusion the mean serum concentration was low, subsequently enrolled patients received the drug every 4 h. A few patients received the drug intramuscularly. At the end of parenteral cefamandole therapy, the patients were treated with an appropriate orally administered antimicrobial agent. The adequacy of oral therapy was monitored by measurement of serum antibiotic levels or of serum antibacterial activity.
Toxicity monitoring. All patients were observed closely for possible adverse effects during the period of cefamandole administration. Additionally, liver function tests (bilirubin, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, and alkaline phosphatase), renal function tests (blood urea nitrogen, serum creatinine, and urinalysis), complete blood counts, and Coombs' test were performed before treatment and were repeated during therapy (between days 6 and 8) and 1 to 2 days after the end of cefamandole therapy.
Pharmacokinetic studies. Cefamandole was infused over a 30-min period, and blood specimens were obtained at 1, 2, and 3 h after the end of the infusion. Blood specimens for determination of cefamandole levels were obtained after the first dose of the drug and between treatment days 3 and 6. When we found no appreciable differences between the serum levels and half-lives measured after the first dose of the drug and those measured after multiple doses, specimens were obtained from subsequently enrolled patients on only one occasion during the first 2 days of treatment. Serum was separated and frozen at -20°C. The sera were assayed for cefamandole concentrations by the microbioassay method with Bacillus subtilis (ATCC 6633) as the test organism (18) . The minimal inhibitory concentration and the minimal bactericidal concentration of cefamandole for the organisms recovered from patients in this study were determined by the broth dilution method.
RESULTS
The clinical characteristics of the 28 patients with demonstrable infections are summarized in who received the drug intramuscularly. In six patients, serum levels were determined after the first dose and again after multiple doses of the antibiotic. Although there was variation among patients, the serum levels and serum half-lives were similar after the first dose and after multiple doses in the same patient, suggesting that there was no drug accumulation with repeated dosing. There was no correlation between the ages of the patients and the serum levels and half-lives of cefamandole. The serum levels after intramuscular administration were higher than levels at comparable intervals after intravenous administration; however, half-lives were similar after intramuscular or intravenous administration.
A semilogarithmic plot of the mean serum cefamandole levels at 1, 2, and 3 h showed a linear decline in the drug concentration (Fig. 1) .
In eight additional patients (age range, 1.3 to 14.8 years; mean, 7.1 years), cefamandole (37.5 mg/kg) was administered intravenously every 6 h (data not shown). The mean half-life after 11 observations was 32 min (range, 22 to 40 min). Serum cefamandole levels at 4 h after the infusion ranged from 0.5 to 1.9 ,ug/ml (mean, 0.9 ,ug/ ml). Table 3 is a summary of the data on penetration of cefamandole into joint fluid. It is not Serum   fluid   9  5 min  2125  13  lh  9  20  4h  18  12  3h  24  40  20  2h  5  5  21 lh 15 possible to calculate the ratio of cefamandole concentration in serum and joint fluid because of the limited number of observations. However, it is readily apparent that the joint fluid concentration of cefamandole is above the miniimal bactericidal concentration for every organism encountered during this study. DISCUSSION The safety and efficacy of cefamandole in the treatment of various infections have been established in adults (4, 8, 9, 14, 15, 19) and in children (2, 17) . In a multicenter evaluation (11) cefamandole was found to be effective in the treatment of bone and joint infections in 26 of 30 patients. The patients were mostly adults, and none had infections caused by H. influenzae. The adequacy of oral antimicrobial therapy after a short period of parenteral antibiotic therapy in the treatment of bone and joint infections has been validated by recent observations (6, 10, 16, 20) . Our patients with skeletal infections responded satisfactorily during the initial period of cefamandole therapy.
Like many other fi-lactam antiobiotics, cefamandole appears to diffuse well into joint fluid and bone tissue. Observations by Levine and McCain (11) and our data show that cefamandole attains good levels in joint fluid during treatment for pyogenic arthritis. Although there are no data on the concentration of cefamandole in infected bone, the concentration of the drug ranges from 1.9 to 44 ,ug/g of bone tissue in individuals without bone infection (11) .
Walker and Gahol (21) administered cefamandole (37 mg/kg) intravenously every 6 h in children over 1 year of age and found a mean serum level of 1.5 ,ug/ml at 6 h after dosing. In the few patients that we treated with a similar dose, the extrapolated 6-h mean level was 0.1 ,ug/ml.
When we administered cefamandole at 25 mg/ kg, the mean serum level at 3 h after the infusion was only 1.8 ,ug/ml. The serum half-lives that we observed were approximately half those reported by Walker and Gahol. Published reports (5, 12) indicate that 8 to 10% of S. aureus and H. influenzae isolates are inhibited only by cefa-mandole levels of greater than 0.6 ug/ml. Therefore, we believe that cefamandole should be administered every 4 h in the treatment of serious infections.
The reported values for serum half-lives of intravenously administered cefamandole in adults ranged between 27 and 72 min (13) . The half-lives were longer after intramuscular administration. Agbayani et al. (1) observed mean half-lives in newborn infants ranging from 56 to 72 min, depending on the dose and route of administration of the drug. In a study by Chang et al. (3), cefamandole half-lives in children 3 months to 13 years of age were 47 min after intravenous administration and 58.5 min after intramuscular administration. Half-lives after intramuscular administration were longer in children over 1 year of age than in infants, but after intravenous administration cefamandole half-lives were similar in children of all ages. Walker and Gahol (21) estimated that the serum half-life of cefamandole after an intravenous dose is between 60 and 90 min in children over 1 year of age and approximately 2 h in children younger than 3 months of age. Our data suggest that cefamandole half-lives in children are shorter than previously reported and that elimination half-lives are comparable after intravenous and intramuscular administrations.
